Piper Sandler analyst Matt O’Brien raised the firm’s price target on Sight Sciences (SGHT) to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes shares of Sight Sciences have seen some recovery year-to-date, up +10.7% after a challenging 2024 campaign. Piper likes the company’s MIGS technology and views the company’s dry eye asset as an intriguing product in a large end-market, but it wrestles with uncertainty in the glaucoma business, namely the late ’24 LCD reimbursement change and potential trialing of a recent competitor product launch. Further, Piper suspects Sight Sciences will need to access the capital markets in the next 1-2 years, and it thinks it will take dry eye at least several quarters to find its stride with the change in commercial/reimbursement strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences: Hold Rating Amid Promising TearCare Potential and Market Access Challenges
- Sight Sciences Holds Annual Stockholders Meeting
- Sight Sciences price target raised to $3.60 from $3.20 at Citi
- Sight Sciences, Inc. Earnings Call: Mixed Results and Strategic Focus
- Sight Sciences price target raised to $3 from $2.50 at Lake Street